IMI Paradigm

Patients Active in Research and Dialogues for an Improved Generation of Medicines (PARADIGM) is a 30-month IMI-funded project (from March 2018 to August 2020) with public and private partners representing patient organisations, pharmaceutical industry, not-for-profit organisations, regulators and HTA bodies.

The main objective is to provide a framework that will enable a meaningful, impactful, ethical and sustainable patient engagement.

As EUPATI is focusing on patient education to enable patient engagement, the collaboration with IMI-PARADIGM is very important when it comes to sharing case studies, inputting in working groups and organising the Patient Engagement Open Forum.